Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: A pilot study

Nephrology Dialysis Transplantation

Volumn 20, Issue 1, 2005, Pages 135-140

  Leehey, David J ^a,c   Palubiak, David J ^a   Chebrolu, Srivasa ^a   Agarwal, Rajiv ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Hines VA Hospital (151H)   (United States)

Author keywords

Anaemia; Chronic kidney failure; Iron; Malondialdehyde; Oxidative stress; Randomized controlled trial

Indexed keywords

ACETYLCYSTEINE; ALBUMIN; ENZYME; FERRIC GLUCONATE; MALONALDEHYDE; N ACETYL BETA GLUCOSAMINIDASE; PLACEBO; PROTEIN; TRANSFERRIN; UREA;

ACUTE DISEASE; AGED; ANEMIA; ARTICLE; BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORIMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG TOLERABILITY; ENZYMURIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTENSION; IRON THERAPY; KIDNEY INJURY; MALE; OXIDATIVE STRESS; PILOT STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL SYSTEM PARAMETERS; RISK BENEFIT ANALYSIS; URINE LEVEL;

ACETYLCYSTEINE; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANEMIA; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FERRIC COMPOUNDS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PILOT PROJECTS; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD;

EID: 13444269669     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh565     Document Type: Article

References (29)

1. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13: 504-510
2. Nissenson AR, Strobos J. Iron deficiency in patients with renal failure. Kidney Int Suppl 1999; 69: S18-S21
3. Valderrabano F, Jofre R, Lopez-Gomez JM. Quality of life in end-stage renal disease patients. Am J Kidney Dis 2001; 38: 443-464
4. Besarab A. Iron and cardiac disease in the end-stage renal disease setting. Am J Kidney Dis 1999; 34: S18-S24
5. Agarwal R, Warnock D. Issues related to iron replacement in chronic kidney disease. Semin Nephrol 2002; 22: 479-487
6. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103
7. Zager RA, Johnson ACM, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 2004; 66: 144-156
8. Shah SV. Role of iron in progressive renal disease. Am J Kidney Dis 2001; 37: S30-S33
9. Lim CS, Vaziri ND. The effects of iron dextran on the oxidative stress and cardiovascular tissues of rats with chronic renal failure. Kidney Int 2004; 65: 1802-1809
10. Handelman GJ, Walter MF, Adhikarla R et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 59: 1960-1966
11. Spittle MA, Hoenich NA, Handelman GJ et al. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 2001; 38: 1408-1413
12. Salahudeen AK, Oliver B, Bower JD, Roberts LJ. Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 2001; 60: 1525-1531
13. Roob JM, Khoschsorur G, Tiran A et al. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000; 11: 539-549
14. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289
15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S76-S92
16. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37: S182-S238
17. Williams J, Evans RW, Moreton K. The iron-binding properties of hen ovotransferrin. Biochem J 1978; 173: 533-539
18. Rayman MP, Barlis J, Evans RW et al. Abnormal iron parameters in the pregnancy syndrome preeclampsia. Am J Obstet Gynecol 2002; 187: 412-418
19. Agarwal R, Chase SD. Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J Chromatogr B 2002; 775: 121-126
20. Michael B, Coyne DW, Fishbane S et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002; 61: 1830-1839
21. Folkert VW. Safety of high doses of non-dextran irons. Semin Dial 2003; 16: 285-286
22. Coyne DW, Adkinson NF, Nissenson AR et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003; 63: 217-224
23. Rooyakkers TM, Stroes ES, Kooistra MP et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002; 32 [Suppl 1]: 9-16
24. Herrera J, Nava M, Romero F, Rodriguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 2001; 37: 750-757
25. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999; 14: 2680-2687
26. Tovbin D, Mazor D, Vorobiov M et al. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 2002; 40: 1005-1012
27. Michelis R, Gery R, Sela S et al. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2002; 18: 924-930
28. Sengoelge G, Kletzmayr J, Ferrara I et al. Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 2003; 14: 2639-2644
29. Tepel M, van der GM, Schwarzfeld C et al. Prevention of radiographic-contrast-agent induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180-184